# Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

> **NCT03836053** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 23 (actual)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** AMG 420

## Key facts

- **NCT ID:** NCT03836053
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-04
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836053, "Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03836053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*